Granted Patent B2

US 12,391,768 · App. 18/451,751 · Granted Aug 19, 2025

Inventors: Andrew Buchanan (Cambridge, GB); Sven Nylander (Sodertalje, SE); Mark Penney (Cambridge, GB); Philip Newton (Cambridge, GB); Feenagh Keyes (Cambridge, GB); Tord Inghardt (Sodertalje, SE)

Assignee: Medimmune Limited

C07K16/44C07D487/04A61K2039/505C07K2317/21C07K2317/24C07K2317/54C07K2317/55C07K2317/565C07K2317/569C07K2317/622C07K2317/626C07K2317/76C07K2317/92C07K2317/94

Abstract

Claims (24)

1. Nucleic acid encoding an antibody or a fragment thereof comprising complementarity-determining region (CDR) combinations selected from the group consisting of:

SEQ ID NO:53 (VH CDR1), SEQ ID NO:54 (VH CDR2), SEQ ID NO:55 (VH CDR3), SEQ ID NO:58 (VL CDR1), SEQ ID NO:59 (VL CDR2), and SEQ ID NO:60 (VL CDR3);

SEQ ID NO:63 (VH CDR1), SEQ ID NO:64 (VH CDR2), SEQ ID NO:65 (VH CDR3), SEQ ID NO:68 (VL CDR1), SEQ ID NO:69 (VL CDR2), and SEQ ID NO:70 (VL CDR3); and

SEQ ID NO:73 (VH CDR1), SEQ ID NO:74 (VH CDR2), SEQ ID NO:75 (VH CDR3), SEQ ID NO:78 (VL CDR1), SEQ ID NO:79 (VL CDR2), and SEQ ID NO:80 (VL CDR3);

wherein the antibody or fragment thereof binds to ticagrelor ((1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol) or a metabolite or derivative thereof.

2. The nucleic acid of claim 1 , wherein the antibody or fragment thereof comprises CDRs comprising: SEQ ID NO:73 (VH CDR1), SEQ ID NO:74 (VH CDR2), SEQ ID NO: 75 (VH CDR3), SEQ ID NO:78 (VL CDR1), SEQ ID NO:79 (VL CDR2), and SEQ ID NO: 80 (VL CDR3).

3. The nucleic acid of claim 1 , wherein the antibody or fragment thereof comprises a variable heavy chain (VH) region and a variable light chain (VL) region, wherein:

the VH has an amino acid sequence according to SEQ ID NO: 52 and the VL has an amino acid sequence according to SEQ ID NO: 57; or

the VH has an amino acid sequence according to SEQ ID NO: 62 and the VL has an amino acid sequence according to SEQ ID NO: 67; or

the VH has an amino acid sequence according to SEQ ID NO: 72 and the VL has an amino acid sequence according to SEQ ID NO: 77.

4. The nucleic acid of claim 1 , wherein the antibody or fragment thereof comprises a VH region and a VL region, wherein the VH has an amino acid sequence according to SEQ ID NO: 72 and the VL has an amino acid sequence according to SEQ ID NO: 77.

5. The nucleic acid of claim 2 , wherein the antibody or fragment thereof comprises a VH region and a VL region, wherein the VH has an amino acid sequence according to SEQ ID NO: 72 and the VL has an amino acid sequence according to SEQ ID NO: 77.

6. The nucleic acid of claim 1 , wherein the antibody or fragment thereof is selected from the group consisting of a monoclonal antibody, a humanized antibody, and a human antibody.

7. The nucleic acid of claim 1 , wherein the antibody fragment is a Fab or a F(ab′)2.

8. The nucleic acid of claim 1 , wherein the antibody fragment is a Fab.

9. The nucleic acid of claim 8 , wherein the Fab is humanized.

10. The nucleic acid of claim 2 , wherein the antibody fragment is a Fab.

11. The nucleic acid of claim 10 , wherein the Fab is humanized.

12. One or more vectors comprising the nucleic acid of claim 1 .

13. One or more vectors comprising the nucleic acid of claim 2 .

14. A host cell comprising the one or more vectors of claim 12 .

15. A host cell comprising the one or more vectors of claim 13 .

16. A method of producing an antibody or a fragment thereof that binds to ticagrelor, comprising culturing the host cell of claim 14 under conditions for expression of the antibody or fragment thereof.

17. A method of producing an antibody or a fragment thereof that binds to ticagrelor, comprising culturing the host cell of claim 15 under conditions for expression of the antibody or fragment thereof.

Continuity (7)

References Cited (175)